Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Blood (2022) 140 (Supplement 1): 1784–1787.

https://doi.org/10.1182/blood-2022-159047

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Philipp le Coutre, Joachim R Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert

Blood (2022) 140 (Supplement 1): 12202–12203.

https://doi.org/10.1182/blood-2022-162281

Published: 2022

Journal Articles

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H.H. Brummendorf

Blood (2022) 140 (Supplement 1): 12194–12196.

https://doi.org/10.1182/blood-2022-164607

Published: 2022

Journal Articles

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R. Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H Brümmendorf

Blood (2021) 138 (Supplement 1): 3608.

https://doi.org/10.1182/blood-2021-151240

Published: 2021

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood (2021) 138 (Supplement 1): 139.

https://doi.org/10.1182/blood-2021-148682

Published: 2021

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Ashwini M Patil, MSc, Stefanie Kesper, Vishal Khairnar, PhD, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, PD, MD

Blood (2019) 134 (Supplement_1): 2537.

https://doi.org/10.1182/blood-2019-125331

Published: 2019

Journal Articles

Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors

Karlotta E Kahmann, Stefanie Kesper, Marco Luciani, Michael Möllmann, Hugh Y. Rienhoff, Jr., MD, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, MD

Blood (2018) 132 (Supplement 1): 2645.

https://doi.org/10.1182/blood-2018-99-113887

Published: 2018

Journal Articles

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease

Marion Lenglet, Florence Robriquet, Klaus Schwarz, Carme Camps, Anne Couturier, David Hoogewijs, Alexandre Buffet, Samantha J. L. Knight, Sophie Gad, Sophie Couvé, Franck Chesnel, Mathilde Pacault, Pierre Lindenbaum, Sylvie Job, Solenne Dumont, Thomas Besnard, Marine Cornec, Helene Dreau, Melissa Pentony, Erika Kvikstad, Sophie Deveaux, Nelly Burnichon, Sophie Ferlicot, Mathias Vilaine, Jean-Michaël Mazzella, Fabrice Airaud, Céline Garrec, Laurence Heidet, Sabine Irtan, Elpis Mantadakis, Karim Bouchireb, Klaus-Michael Debatin, Richard Redon, Stéphane Bezieau, Brigitte Bressac-de Paillerets, Bin Tean Teh, François Girodon, Maria-Luigia Randi, Maria Caterina Putti, Vincent Bours, Richard Van Wijk, Joachim R. Göthert, Antonis Kattamis, Nicolas Janin, Celeste Bento, Jenny C. Taylor, Yannick Arlot-Bonnemains, Stéphane Richard, Anne-Paule Gimenez-Roqueplo, Holger Cario, Betty Gardie

Blood (2018) 132 (5): 469–483.

https://doi.org/10.1182/blood-2018-03-838235

Published: 2018

Includes: Supplemental data

Journal Articles

HIF-1α Promotes Cbfbeta-SMMHC-Induced Acute Myeloid Leukemia Development

Benedikt W. Pelzer, Anita Hollenbeck, PhD, Stefanie Weber, Bertram Opalka, PhD, Lucio H. Castilla, PhD, Ulrich Dührsen, MD, Joachim R. Göthert, MD

Blood (2016) 128 (22): 1559.

https://doi.org/10.1182/blood.V128.22.1559.1559

Published: 2016

Journal Articles

The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis

Kristina B. Schoedel, Mina N. F. Morcos, Thomas Zerjatke, Ingo Roeder, Tatyana Grinenko, David Voehringer, Joachim R. Göthert, Claudia Waskow, Axel Roers, Alexander Gerbaulet

Blood (2016) 128 (19): 2285–2296.

https://doi.org/10.1182/blood-2016-03-706010

Published: 2016

Includes: Supplemental data

Journal Articles

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Mirle Schemionek, Christian Elling, Ulrich Steidl, Nicole Bäumer, Ashley Hamilton, Tilmann Spieker, Joachim R. Göthert, Martin Stehling, Amy Wagers, Claudia S. Huettner, Daniel G. Tenen, Lara Tickenbrock, Wolfgang E. Berdel, Hubert Serve, Tessa L. Holyoake, Carsten Müller-Tidow, Steffen Koschmieder

Blood (2010) 115 (16): 3185–3195.

https://doi.org/10.1182/blood-2009-04-215376

Published: 2010

Journal Articles

Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor

Lisette M. Acevedo, Samuel Barillas, Sara M. Weis, Joachim R. Göthert, David A. Cheresh

Blood (2008) 111 (5): 2674–2680.

https://doi.org/10.1182/blood-2007-08-110205

Published: 2008

Includes: Supplemental data

Journal Articles

NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis

Joachim R. Göthert, Rachael L. Brake, Monique Smeets, Ulrich Dührsen, C. Glenn Begley, David J. Izon

Blood (2007) 110 (10): 3753–3762.

https://doi.org/10.1182/blood-2006-12-063644

Published: 2007

Includes: Supplemental data

Journal Articles

A Novel Cellular Pathway of SCL T-Leukemogenesis Revealed by a Conditional Transgenic Mouse Model.

Joachim R. Gothert, Rachael Brake, C. Glenn Begley, David J. Izon

Blood (2006) 108 (11): 1835.

https://doi.org/10.1182/blood.V108.11.1835.1835

Published: 2006

Journal Articles

In Vivo Fate Tracing Studies Using the SCL Stem Cell Enhancer: Embryonic Hematopoietic Stem Cells Significantly Contribute to Adult Hematopoiesis.

Joachim R. Gothert, Sonja E. Gustin, Mark A. Hall, Anthony R. Green, Berthold Gottgens, David J. Izon, C. Glenn Begley

Blood (2004) 104 (11): 559.

https://doi.org/10.1182/blood.V104.11.559.559

Published: 2004

NARROW

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease

HIF-1α Promotes Cbfbeta-SMMHC-Induced Acute Myeloid Leukemia Development

The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor

NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis

A Novel Cellular Pathway of SCL T-Leukemogenesis Revealed by a Conditional Transgenic Mouse Model.

In Vivo Fate Tracing Studies Using the SCL Stem Cell Enhancer: Embryonic Hematopoietic Stem Cells Significantly Contribute to Adult Hematopoiesis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only